Overview

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine efficacy and safety of paclitaxel, bevacizumab and enzastaurin versus paclitaxel, bevacizumab, and placebo in participants who are diagnosed with locally recurrent or metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Genentech, Inc.
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Paclitaxel